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InﬂammationAtherogenesis is thepathogenetic process leading to formation of the atheroma lesion. It is associated to a chronic
inﬂammatory state initially stimulated by an aberrant accumulation of lipid molecules beyond the endothelial
barrier. This event triggers a cascade of deleterious eventsmainly through immune cell stimulationwith the con-
sequent liberation of potent pro-inﬂammatory and tissue damaging mediators. The atherogenetic process im-
plies marked modiﬁcations of endothelial cell functions and a radical change in the endothelial–leukocyte
interaction pattern. Moreover, accumulating evidence shows an important link between microvascular and in-
ﬂammatory responses and major cardiovascular risk factors. This review illustrates the current knowledge on
the effects of obesity, hypercholesterolemia and diabetes on microcirculation; their pathophysiological implica-
tions will be discussed.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In most organs, microcirculation is composed of three anatomically
and functionally distinct segments: arterioles, capillaries and venules.
Arterioles are well innervated and anatomically characterized by endo-
thelium surrounded by a smooth muscle cell containing wall and a
diameter ranging from 10 to 100 μm. Typically, arterioles display a
divergent branching pattern so that blood ﬂows from one arteriole
into two branches at each bifurcation. Arterioles are highly responsive
to sympathetic vasoconstriction and represent amajor player in the reg-
ulation of systemic vascular resistance. Because of these characteristics,
the regulation of blood ﬂow and ultimately oxygen delivery represent
the primary function of arterioles. In addition arterioles, by participating
to the regulation of capillary hydrostatic pressure, inﬂuence capillary
ﬂuid exchange [1,2].lial cells; ESAM, endothelial cell-
nmolecule 1; JAM, junction ad-
1, mucosal addressin cell adhe-
SGL-1, P-selectin glycoprotein
dismutase; V-CAM-1, vascular
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. This is an open access article underBlood ﬂows from arterioles into capillaries, 5–10 μM calibre single
endothelial cell layer vessels surrounded by basement membrane and
devoid of smooth muscle cell wall and innervation. In some organs,
however, a circular band of smooth muscle at the entrance of the capil-
lary (precapillary sphincter) can regulate the number of perfused capil-
laries [1,2].
Capillaries ensure large surface area and relatively high permeability
to favour the exchange of ﬂuids, gases, electrolytes and macromole-
cules. In different organs, the endothelial wall differs for its structural
organization and permeability. In the liver, spleen and bone marrow
gaps in both the endothelial layers and the basement membrane result
in very high permeability of capillaries. Fenestrated capillaries are pres-
ent in the intestinal mucosa, renal glomeruli and exocrine glands where
endothelial cells display wide intercellular clefts surrounded by a con-
tinuous basement membrane. Continuous capillaries are found in the
central nervous system, skin, muscle and the lung where intercellular
gaps are tight and basement membrane is continuous. These capillaries
display the lowest permeability [1–3].
Venules are small exchange vessels butwith a larger caliber than the
corresponding arterioles (10–50 μM caliber), resulting in a lower ﬂow
velocity and wall shear stress that promote leukocyte margination and
facilitate adhesion to the vessel wall. Venules are composed of an endo-
thelial cell layer surrounded by a basement membrane. Smooth muscle
cells are present in larger venules but not in small postcapillary venules.
The presence of smooth muscle and sympathetic innervation in largerthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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drostatic pressure [2,3]. Due to their anatomical architecture resulting in
relatively low permeability, ﬂuid and macromolecules exchange occurs
predominantly at venular junctions. Leukocyte margination is favoured
in venules because of erythrocyte tendency to aggregate at low shear
stress forces occurring in the central portion of venules. Erythrocyte ag-
gregation in turn pushes leukocytes toward the vessel wall. In addition,
the ﬂow discharged by a capillary into a venule at site of conﬂuent junc-
tions is located to a region close to the venule wall thus promoting leu-
kocytes to take contact with the endothelium. Finally, the most
important factor determining the prevalence of leukocyte adhesion to
venule walls during inﬂammation is the selective expression of adhe-
sion molecules by venule but not arteriole or capillary endothelial
cells [1,2,4].
2. Inﬂammatory state of microcirculation associated
to atherogenesis
Under normal conditions, vascular endothelial cells subserve several
tasks that constitute the “endothelial function” including the regulation
of blood ﬂow, blood ﬂuidity, vessel wall permeability and interactions
with circulating leukocytes.
Blood ﬂow ﬂuidity is modulated through the regulation of the tone
of surrounding vascular smooth muscle cells, that in turn, depends on
the balance between vasoconstriction and vasorelaxant signals. Endo-
thelial cell-dependent vasorelaxation of SMC is achieved through the
production of nitric oxide. Nitric oxide is highly reactive (having a life-
time of a few seconds), yet diffuses freely across membranes. NO acts
through the stimulation of the heterodimeric enzyme soluble guanylate
cyclase, with subsequent formation of cyclic GMP. Cyclic GMP activates
protein kinase G, which causes phosphorylation of myosin light chain
phosphatase, and therefore inactivation of myosin light-chain kinase,
causing smooth muscle relaxation through the dephosphorylation of
the myosin light chain [5].
Endothelial cells actively inhibit blood coagulation ensuring blood
ﬂuidity through several mechanisms such as the expression of coagula-
tion cascade inhibitors including heparane sulphate proteoglycans,
inhibitors of tissue factor pathways, and thrombomodulin. In addition
ECs inhibit platelet activation by releasing NO and prostacyclin [6,7].
In physiological conditions, plasmatic proteins are contained inside
vascular lumen of continuous capillaries, the structure of junctions be-
tween adjacent ECs that include tight and adherens junctions. The per-
meability properties of capillaries depend on the structural organization
and the presence of intercellular junction structures that vary consider-
ably in different anatomical locations. Junctional structures are tighter
in the capillaries of the central nervous system, in the liver and
spleen sinusoidal capillaries and are characterized by discontinuous
intercellular junctions that enable blood contact with underlying tis-
sue. However, in most tissues, capillary ECs normally block extrava-
sation of plasmatic proteins as small as albumin. On the other hand,
they operate active transport of proteins from capillary lumen to tis-
sue via vesicular transport [8].
In normal conditions, endothelial cells have rare interactions with
circulating leukocytes, thus representing a barrier between tissues and
inﬂammatory cells. In non-inﬂamed vasculature leukocyte–ECs, inter-
action is limited because of the very low constitutive expression of sur-
face adhesionmolecules such as, ICAM-1, VCAM-1 and E-selectin aswell
as the compartmentalization of P-selectin and chemokines into endo-
thelial intracellular vesicles namedWeibel–Palade bodies [2,9]. In addi-
tion, resting ECs stimulated by shear stress express NO that inhibits
proinﬂammatory gene transcription, release of Wiebel–Palade body
content and leukocyte activation (discussed below).
Atherosclerosis involves the formation of lesions in the arteries char-
acterized by lipid accumulation, inﬂammation, cell death and ﬁbrosis.
These lesions known as atherosclerotic plaques grow and evolve over
time with the consequent decrease of the vasal section. A limited andoften insufﬁcient blood ﬂow accompanied by stenosis due to modiﬁca-
tion of blood vessel plasticity, leads to clinical complications. However,
themost serious complications arise from lesion rupture and sudden ex-
posure of thrombotic substances to circulating blood leading to abrupt
formation of blood clots and occlusion. The atherogenic process involves
three major steps: an early and persisting inﬂammatory component, a
proliferative response and, ultimately, a mural thrombosis that is poten-
tially responsible for vascular occlusion.
Although atherosclerotic lesions occur in large arteries, the up-
regulated expression of adhesion molecules characteristic of EC acti-
vation, the reduced endothelium-dependent vasodilatation as well
as oxidative stress are not conﬁned to lesion-prone arteries where
factors other than EC activation (e.g. elevated shear stress) might
act to determine atheroma formation. Atherosclerosis is associated
with a systemic inﬂammatory state characterized by endothelial
and blood cell activation as well as increased plasmatic concentra-
tion of inﬂammatory factors and endothelial dysfunction consisting
in reduced endothelium-dependent vasodilation [10]. Parameters
such as the circulating concentrations of proinﬂammatory factors
or soluble isoforms of adhesion molecules have been proposed as
biomarkers for the assessment of cardiovascular risk. Enhanced pro-
duction of inﬂammatory mediators such as cytokines, chemokines
and reactive oxygen species occurs in the atherosclerotic lesions de-
termining and sustaining local intramural inﬂammation. However,
inﬂammatorymediators can also be released in the circulation deter-
mining systemic inﬂammation with the involvement of themicrocir-
culation. Alternatively, cardiovascular risk factors as for example
elevated blood cholesterol levels, hypertension, diabetes, obesity
and cigarette smoke might directly stimulate microvascular endo-
thelial cell activation with consequent release of inﬂammatory media-
tors and soluble isoforms of adhesion molecules, thus determining
microvascular dysfunction and the atherosclerosis-associated systemic
inﬂammatory state [11]. In support of this hypothesis, many observa-
tions have indicated that the presence of cardiovascular risk factors
such as hypercholesterolemia, obesity, hypertension and diabetes
inducesmicrovascular responses consistentwith the induction of an in-
ﬂammatory phenotype [12]. In both scenarios, due to its preponderant
surface area, microcirculationwould quantitatively represent themajor
source of circulating inﬂammatory mediators.
Accumulating evidence suggests that oxidative stress represents a
main pathogenic mechanism underlying the development and the pro-
gression of atherosclerosis. Oxidative stress is deﬁned as an imbalance
between oxidants and antioxidants in favour of the former. Reactive ox-
ygen species (ROS), including superoxide anions (O2−), hydrogen perox-
ide, and hydroxyl radicals are produced by a variety of cell types
including endothelial cells, phagocytes and smooth muscle cells. Free
radicals such as O2− and hydroxyl radicals are highly reactive and hold
exalted oxidizing activity. The activity of enzymes such as nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase and xanthine oxi-
dase, as well as the mitochondrial redox cycle can generate ROS.
Endothelial cells, vascular smooth muscle cells, and monocyte/mac-
rophage cells contain potent defence systems against ROS, including the
enzymes superoxide dismutase, catalase, and glutathione peroxidase,
and non-enzymatic antioxidants. Nonetheless, excessive ROS produc-
tion may occur and cause endothelial dysfunction, inﬂammation of the
arterial wall, and atherosclerosis. Endothelial dysfunction is a very
early marker of endothelial suffering. Being located between the blood
and the vessel wall, the vascular endothelium has a strategic position
in the cardiovascular system. NO produced by the endothelium has
potent vasorelaxant activity, but it is also highly reactivewithO2. NOox-
idation generates peroxynitrite, which is devoid of vasodilatory proper-
ties. Reduced NO bioavailability is therefore associated with impaired
response to all vasodilators that act primarily by stimulating the endo-
thelial release of NO. Notably, increased oxidative stress and endothelial
dysfunction have been demonstrated in subjects with cardiovascular
risk factors such as diabetes, hypercholesterolemia, and hypertension,
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cular endothelium as for example the regulation of blood coagulation
and the recruitment of circulating leukocytes. By downregulating the
surface expression of adhesionmolecules, NO contributes to limit endo-
thelial cell–leukocyte interaction thus dampening inﬂammation. In ad-
dition, NO exerts antithrombogenic and antiproliferative effects [13].
Reduced NO levels would therefore negatively impact vascular physiol-
ogy. In addition, increased ROS concentrations translate into augmented
oxidation of low-density lipoproteins, which are taken up by macro-
phages, cause foam cell formation and induce vascular inﬂammation
[14–16]. A relevant quota of superoxide comes from the transfer of elec-
trons from NADPH to oxygen catalyzed by membrane-bound NADPH
oxidases expressed by endothelial cells, vascular smooth muscle
cells, ﬁbroblasts, and phagocytes. Atherosclerosis is associated
with increased expression of NADPH oxidases. Thus, it is not sur-
prising that the activity of such enzymes represents a major target
of pharmacological treatment aimed at reducing atherosclerosis
progression. In this context, it is worthy to point out that the
NADPH-oxidase-mediated O2-production is upregulated by angio-
tensin II (Ang II); therefore, Ang II type 1 (AT1)-receptor blockade
can effectively reduce oxidative stress and inﬂammation in patients
with hypertension, established coronary heart disease, or metabolic
syndrome [17]. Moreover, hydroxymethylglutarylcoenzyme A reduc-
tase inhibitors (statins) inhibit cholesterol synthesis, as well as the for-
mation of the of NADPH oxidases, thereby attenuating oxidative stress.
As a result, statins and renin–angiotensin system blockers improve
endothelium-dependent vasodilation and reduce circulating inﬂamma-
tory molecules [18].
3. Oxidative stress and hypercholesterolemia
Microvascular inﬂammatory and thrombogenic response has been
observed in several studies involving animal models of diet-induced
hypercholesterolemia. This microvascular endothelial dysfunction is
characterized by oxidative stress [19–21]. The resulting increased ROS
generation and reduced NO bioavailability translate into impaired
endothelium-dependent arteriolar vasodilation [22] and increased ex-
pression of adhesion molecules in the post capillary venule endothelium
[23], the latter causing increased leukocyte and platelet recruitment. In
turn, the increased interaction betweenECand leukocytes sustains oxida-
tive stress [19,24].
Oxidative stress in post-capillary venules has been shown to occur
early upon the onset of hypercholesterolemia [25,26]. Increased ROS
production also contributes to the generation of oxidized low-density li-
poproteins that, in turn, are knownmediators of inﬂammation and vas-
cular dysfunction in atherosclerosis [27,28].
Among ROS species, whose generation is elicited by hypercholester-
olemia, superoxide is the best characterized and its metabolism can be
taken as paradigmatic of other ROS species.
Superoxide formation can arise by reactions catalyzed by different
enzymes including xanthine oxidase, lipoxygenase and NADPH oxidase.
The latter is expressed by multiple cell types such as endothelial cells,
smooth muscle cells, monocytes, T lymphocytes and platelets [29–31].
Because of its intrinsic toxicity, superoxide levels are controlled by a
tight balance between production and degradation, the latter occurring
primarily by the endogenous scavenger enzyme superoxide dismutase
(SOD). Although SOD competes with NO for superoxide, superoxide–
NO interaction is favoured and generates the toxic product peroxynitrite
yet depleting NO.
Increased ROS production might lead to reduced NO bioavailability
by an indirectmechanism also. For example, the activity of NO synthase
(NOS) isoform expressed by ECs (eNOS) is pivotal for normal regulation
of vascular tone and the maintenance of antithrombogenic and anti-
inﬂammatory endothelial cell phenotype. However, it requires sufﬁ-
cient levels of the cofactors such as tetrahydrobiopterin that are im-
paired in the presence of elevated ROS production. Notably, in theabsence of adequate tetrahydrobiopterin concentration, eNOS turns to
generate superoxide instead of NO, thus further contributing to the
NO/ROS imbalance [32]. In addition, NOS activity can also be reduced
as a result of the increased levels of asymmetric dimethylarginine
(ADMA) occurring during hypercholesterolemia [33]. Interestingly, in
hypercholesterolemic patients with impairment of the endothelium-
dependent dilation of the epicardial coronary arteries, vascular function
can be restored reducing serum cholesterol [34]. Themechanismunder-
lying this dysfunction involves the reduced ability of substances such as
acetylcholine or bradykinin that stimulate EC to release NO that, in turn,
acts on VSMC. Stimulation with a NO donor, restores normal vasodila-
tion thus indicating that VSMC responsiveness to NO is preserved [22,
23]. Two additional observations further support the hypothesis that
the hypercholesterolemia-induced vascular dysfunction is, at least in
part,mediated by ROS/NO imbalance: administration of L-arginine, sub-
strate of NO synthase, or of superoxide dismutase reversed vascular
function impairment in hypercholesterolemic animals [22,35].
Oxidative stress to which microvascular endothelium is exposed is
signiﬁcantly sustained by EC interaction with inﬂammatory cells. Such
interaction occurs primarily in post capillary venules but can affect the
function of other microvascular segments. For example it has been
shown that neutrophil adhesion to venular endothelium contributes
to arteriolar dysfunction [22].
4. Leukocyte-endothelial cell interaction
Inﬂammatory state, aswell as hypercholesterolemia, induces upreg-
ulated expression of adhesion molecules by EC and circulating leuko-
cytes thus favouring blood cell recruitment.
Adhesion molecules, with some exception, belong to one of three
major families: selectins, integrins and immunoglobulins. Selectins bind
to sialyl-Lewis X-like carbohydrate ligands presented by sialomucin-like
surface molecules including P-selectin glycoprotein ligand 1 (PSGL-1)
[36].
P and E-selectin expressions are generally upregulated on endo-
thelium in most inﬂammatory processes and represent important
determinants for leukocyte recruitment. L-selectin on leukocyte
membrane can also bind PSGL-1 expressed on other leukocyte thus
enabling leukocyte capture by intravascular adherent leukocytes. In
the context of inﬂammation, P selectin plays a pivotal role among
molecules expressed by endothelial cells. P selectin can be rapidly
translocated to the plasmatic membrane of endothelial cells from
the Weibel–Palade bodies upon exposure to inﬂammatory stimuli.
Once on the surface, P selectin supports both leukocyte–EC and
platelet–EC interaction. P selectin deﬁciency partially protects from
atherosclerosis and neointima formation after vascular injury [37,
38].
The adhesion properties of selectins and their ligands are regulated
by post-translational modiﬁcations, topographical distribution and
shedding, all of which are inﬂuenced by inﬂammation.
Integrins are transmembrane αβ heterodimers that bind many
extracellular matrix proteins and certain immunoglobulin-like ad-
hesion molecules on other cells [39,40]. The most relevant integrins
for leukocyte recruitment are the heterodimer α1β2 lymphocyte
function-associated antigen 1 (LFA-1), α4β1 very late antigen 4
(VLA-4) and α4β7. Integrins bind a variety of surface molecules of
the immunoglobulin superfamily including intercellular adhesion
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1),
both important ligands for VLA-4 and mucosal addressin cell adhesion
molecule 1 (MAdCAM-1) representing the main ligand for α4β7. Other
relevant members of the immunoglobulin-like adhesion molecules
group include PECAM-1 (CD31) [41], junction adhesion molecule
(JAM)-A, JAM-B and JAM-C [11,42] and endothelial cell-selective adhe-
sion molecule (ESAM) [43].
The current paradigm of the leukocyte recruitment describes a
multi-step process named leukocyte adhesion cascade. The number of
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mechanisms involved afford high degree of speciﬁcity and a wide
variety of potential therapeutic targets. The leukocyte adhesion cascade
begins with ﬁrst contact between leukocyte and endothelium in the
“tethering” step. During the second step named “rolling” cell activation
occurs through the action of chemokines and chemokine-independent
mechanisms. During the rolling step, L-selectin and P-selectin gly-
coprotein ligand-1 (PSGL-1) on the leukocyte, interact with sugars
and P-selectin, respectively, on the endothelial cells. Ligation of im-
munoglobulins, such as intercellular adhesion molecule-1 (ICAM-
1), on the endotheliumby integrins CD11b/CD18on the leukocyte partic-
ipates to strengthen cell–cell interaction and turns some of the rolling
leukocytes into ﬁrmly adherent cells [44,45]. In the ﬁnal stage, migration
into tissue occurs in the presence of appropriate stimuli for both EC and
leukocytes.
Increased leukocyte adhesion is widely diffused in the venular seg-
ments of microcirculation in prolonged hypercholesterolemic conditions,
while the large vessels display distinct foci where leukocyte recruitment
occurs [19–21,23]. Microcirculation response to atherosclerosis-fostering
conditions, such as hypercholesterolemia, includes upregulation of P-
selectin and ICAM-1 in postcapillary venules. Leukocyte recruitment in
the post-capillary venules has been found to be markedly reduced by P-
selectin neutralization [20]. Enhanced leukocyte adherence to the endo-
thelium of post capillary venules has been shown in animal models of
diet-induced hypercholesterolemia.
Animal studies have shown that early upon the establishment of
hypercholesterolemia, the predominant leukocyte subset to be recruited
in post-capillary venules is represented by neutrophils [46]. A key role for
oxidative stress has been demonstrated in the recruitment of neutrophils
induced by elevated cholesterol levels. Mice overexpressing superoxide
scavenger SOD did not display increased leukocyte adhesion in the
post-capillary venules. In keeping,micedeﬁcient for thep47phox compo-
nent of the NADPH oxidase did not display cholesterol induced neutro-
phil recruitment.
5. Role of recruited leukocyte in microvascular inﬂammation
Bone marrow chimera experiments have shown that NADPH oxi-
dase expressed by both endothelial cells and by leukocytes are impor-
tant for determining the inﬂammatory phenotype associated of post-
capillary venules [19]. This ﬁnding suggests that leukocyte recruitment
reinforces inﬂammatory stimulation by locally increasing superoxide
production. The enhanced expression of superoxide due to leukocyte
recruitment might contribute to inﬂammation by directly increasing
circulating concentrations of oxidized LDL that represent another stim-
ulus for increased leukocyte adhesion. In addition, superoxide by de-
pleting NO bioavailability fosters the acquisition of an inﬂammatory
phenotype by endothelial cells. In fact, it has been shown that NO, by in-
ducing the inhibitor κB-α, an inhibitor of NFκB, counteracts cytokine-
induced upregulated expression of adhesionmolecules by the endothe-
lium [47,48]. A relevant source of cytokines reinforcing the acquisition
of inﬂammatory phenotype by endothelial cells is represented by T
lymphocytes. The role of T lymphocytes in the development of
atherosclerostic lesions in the macrovasculature is well documented
[10]. Before plaque development, a contribution of lymphocytes in
determining the inﬂammatory phenotype of endothelial cells in the
microvasculature has been shown inmice lacking B and T cells. Howev-
er T lymphocytes play a prominent role. The two main T lymphocyte
subsets CD4+ and CD8+ both contribute signiﬁcantly to leukocyte ad-
hesion to post-capillary venules occurring in diet-induced hypercholes-
terolemia. In fact, depletion of each subset leads to marked reduction of
microvascular leukocyte recruitment, and the administration of lym-
phocytes to immunodeﬁcient mice restored venular inﬂammation. In
addition, the reconstitution of lymphocyte deﬁcient animals with
splenocytes from IFN-γ deﬁcient mice failed to restore leukocyte
adhesion indicating a non redundant function of such cytokine in theestablishment of the microvascular inﬂammatory phenotype upon
hypercholesterolemia [25]. Similarly, mice lacking the p35 or the p40
subunit of the heterodimeric cytokine IL-12 display reduced leukocyte
adhesion to the microvasculature upon the establishment of diet-
induced hypercholesterolemia [26]. As there is no obvious direct proin-
ﬂammatory effect exerted by IL-12 on endothelial cells or leukocytes, it
is likely that IL-12 effect on microvascular inﬂammation is indirect and
possiblymediated by IFN-γ. Indeed IL-12 is pivotal in the polarization of
T lymphocyte toward a type 1 phenotype characterized by IFN-γ ex-
pression and release upon activation [49]. T cell polarization occurs in
secondary lymphoid tissues when antigens collected in periphery are
presented to naïve T cells by professional antigen presenting cells
(APC, e.g. dendritic cells) [50]. Sustained recognition of APC-borne
MHC-bound antigen by T cell receptor along with appropriate
costimulation is mandatory for naïve T cell activation. Interleukin-12
represents the key signal provided by APCs that induces epigenetic
modiﬁcations of gene expression in the T cell determining its commit-
ment to the type 1 phenotype (IFN-γ but not IL-4 producing) [51]. An-
tigen presentation occurring in the absence of IL-12 favours the
development of type 2T cells producing IL-4 but not IFN-γ. It is worth
noting that IL-12 shares the p40 subunit with IL-23, which in turn,
plays a key role in the development of the IL-17-producing proinﬂamma-
tory CD4+ T cell subset Th17 implicated in chronic inﬂammation [52].
Therefore, the observations made in p40-deﬁcient mice might be due to
the deﬁciency of both Il-12 and Il-23 and consequent blocked develop-
ment of Th1 and Th17 subsets. Although the role of Th17 onmicrovascu-
lar inﬂammation associated to atherosclerosis has not been so far
investigated, it has been shown that IL-17 synergized with IFN-γ to en-
hance IL-6, CXCL8, and CXCL10 secretion [53].
Interleukin-18 has also been implicated in the induction of IFN-γ in
atherogenesis. Gerdes et al. showed IL-18 production by inﬁltrating
macrophages and important levels of IL-18 receptor expression in
human atheroma. IL-18 receptor was expressed by macrophages,
ECs and smooth muscle cells [54]. Stimulation with IL-18 induced IL-6,
IL-8, ICAM-1 and metalloproteinases expression. The study showed,
for the ﬁrst time, the ability of IL-18 alone or in combination with IL-
12 to induce IFN-γ production not only in macrophages but also by
smooth muscle cells.
Many studies indicated IFN-γ as a cytokine participating to athero-
sclerotic plaque development [10,55]. Several mechanisms might link
IFN-γ to vascular dysfunction: IFN-γ stimulatesmacrophages thereby en-
hancing their production of nitric oxide, pro-inﬂammatory cytokines and
pro-thrombotic and vasoactive factors. Additionally, IFN-γ stimulates su-
peroxide production in endothelial cells as well as NADPH activity in
monocytes and granulocytes [56–58]. In keeping, IFN-γ-knockout mice
display reduced oxidative stress in the microcirculation [26]. Notably, in
conditions of reduced NO bioavailability, IFN-γ has been shown to pro-
mote LDL oxidation [59]. Furthermore, IFN-γ is a potent inducer of
ICAM-1 expression on vascular endothelial cells [60] thereby increasing
circulating leukocyte recruitment andmight be implicated in the arterio-
lar dysfunction associated with hypercholesterolemia.
6. Microvascular inﬂammation and obesity
Inﬂammatory phenotype of microvessels is associated with cardio-
vascular risk factors that favour atherosclerosis. In obese subjects the
expanded adipose tissue is also characterized by activated phenotype of
adipocytes and inﬁltrating cells such as macrophages and T cells. Expan-
sion and activation of adipose tissue in obesity translate into increased
release of adipose tissue derived mediators, including inﬂammatory
cytokines such as TNF-α, IL-1, IL-6 and adipokines [61]. In obese subjects
as well as in animal models of obesity, increased local concentration of
cytokines and adipokines in adipose tissue is able to induce evident
signs of inﬂammation in the local microcirculation. In obese mice arteri-
oles, capillaries andpostcapillary venules of visceral adipose tissue under-
go changes that are consistent with active inﬂammation [62]. Also,
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consequent induction of hypoxic state, has been observed. As a conse-
quence, increased expression of HIF-1 alpha and capillary proliferation
is also evident in obese adipose tissue [63]. In addition, leptin, resistin
and other adipokines have been shown to inhibit endothelial dependent
vasodilation [64]. Moreover, activation of capillary endothelium may
contribute to the blood ﬂow reduction due to increased leukocyte adhe-
sion and platelet aggregation. In fact, in adipose tissue of obese animals,
administration of neutralizing anti ICAM-1 antibodies improves capillary
perfusion, likely by reducing vessel ploughing by leukocytes, but also re-
duces vascular permeability. This may indicate that leukocyte adhesion
induces microvascular barrier dysfunction [62]. Similarly, adipose tissue
venules display inﬂammatory phenotype with enhanced expression of
P-selectin, E-selectin and ICAM-1 and increased leukocyte recruitment.
Increased local levels of TNF-α with parallel decreased adiponectin
concentrations as well as increased oxidative stress likely contribute to
enhanced adhesion molecules by endothelial cells as well as to the in-
creased P-selectin expression on platelets accompanied by augmented
platelet–leukocyte aggregates [62,65]. Along with increased formation
of leukocyte–platelet aggregates, in both obese subjects and animal
models of obesity, reduced ﬁbrinolysis and increased thrombogenicity
are also evident. Increased levels of the leptin enhance the risk of throm-
bosis in obese human subjects. Activation of leptin receptor by its natural
ligand induces the activation of phospholipase C and protein kinase C via
intracellular calcium mobilization by PI3K Akt signaling pathway.
Impaired platelet aggregation is observed in both leptin and leptin recep-
tor deﬁcient mice. The pro-thrombotic activity of leptin is counteracted
by adiponectin as suggested by the increased thrombi formation in
adiponectin-knockout mice [66,67]. Adiponectin also inhibits inﬂamma-
tory cell adhesion to the endothelium by counteracting TNF-α induced
NFκB activation via cyclic AMP-dependent mechanism [68] and
consequently inhibits endothelial adhesion molecule expres-
sion. [69]. In addition, adiponectin-dependent increased endothelial
cell cytoskeleton stability reduces vascular permeability in response to
TNF-α or angiotensin II via a cyclic AMP dependent pathway. Conversely,
leptin promotes capillary vascular fenestration and permeability [70].
Notably, during adipogenesis, leptin expression is increased while
adiponectin production is markedly reduced. This suggests that leptin/
adiponectin imbalance participates in promoting the vascular inﬂam-
matory phenotype observed in adipose tissue of obese animals, in par-
ticular the increased coronary microvascular permeability observed at
early stages of obesity. Besides the local effects of increased adipokine
levels occurring in hypertrophic adipose tissue, the accumulation of
such factors in plasma elicits prime endothelial cells for activation in re-
sponse to low concentration of inﬂammatory stimuli, causing the low-
grade systemic inﬂammation that is associated to obesity [71,72].
7. Microvascular inﬂammation and diabetes
Hyperglycemia is an important trigger of oxidative stress. In insulin-
independent tissues, local production of oxidants is enhanced along
with the increase of cellular glucose uptake. Hyperglycemia stimulates
superoxide production by glucose oxidase and NADPH oxidase. Such
effect is mediated by protein kinase C activation [73–76].
Oxidative stress resulting from hyperglycemia has been implicated
in the impaired vascular function that is associated with diabetes.
Diabetes results in enhanced expression of the angiotensin 1 receptor
as well as the p47 and gp91 subunits of the NADPH oxidase complex.
In these conditions, AT1r antagonism or NADPH oxidase inhibition
restores NO-dependent vascular function [77,78].
Hyperglycemia and oxidative stress are recognized as two major
determinants of the increased leukocyte–endothelial cell interaction
occurring in diabetes. Using intravital microscopy, Booth et al. showed
that local glucose levels increased endothelial P-selectin expression
along with leukocyte rolling, ﬁrm adhesion andmigration in post capil-
lary venules [79]. Moreover, similar effects are mimicked in vitro inendothelial cell culture exposed to sera of diabetic patients or advanced
glycation endproduct-albumin and are signiﬁcantly reduced in vivo by
protein C inhibition or the administration of insulin or SOD. In addition,
a possible role for the receptor for advanced glycosylated endproducts
(RAGE) as endothelial adhesion molecule binding to beta 2 integrin on
leukocyte surface, has been proposed [65,79–82].
Oxidative stress, hyperglycemia and increased leukocyte interaction
with the endothelium have been linked to increased vascular permeabil-
ity that is observed in animal models of diabetes and in diabetic subjects.
Diabetes-associated retinopathy and nephropathy represent an example
of major complications due to the loss of the endothelial barrier function.
In fact, oxidative stress, hyperglycemia and increased leukocyte recruit-
ment cause loss of pericytes and endothelial cells, basement membrane
thickening as well as capillary closure in the retina. Consequent hypoxia
stimulates angiogenesis. The blockade of the renin–angiotensin system
by ACE inhibitors or by antagonists of the angiotensin receptor reduces
retinal angiogenesis and the expression of VEGF and VEGFR [83–85].
PPARgamma, VGEF, protein kinase C and the renin–angiotensin system
are believed to play a relevant role in diabetes-induced vascular perme-
ability [86–90].
Increased platelet activation is associated with diabetes. This is
thought to be, at least in part, dependent on a reduced capacity of NO
to inhibit platelet activation possibly as a result of the oxidative stress
associatedwith diabetes and consequent reduction of NObioavailability
[91–99].8. Summary
The evidence linking microvascular and inﬂammatory responses to
cardiovascular risk factors indicates the existence of common events
that initiate and promote these responses. Oxidative stress, reduced
NO bioavailability, and endothelial activation are common early fea-
tures of microvascular responses to cardiovascular risk factors. Another
important consequence of exposure to such risk factors is the increased
extent of tissue damage after ischemia reperfusion. For example, obese,
hypercholesterolemic and diabetic animals display markedly increased
microvascular oxidative stress and enhanced NADPH oxidase activation
compared to animals without risk factors [100–104]. Furthermore,
larger extent of leukocyte and platelet adhesion to endothelial cells in
post-capillary venules is associated with hypercholesterolemia, obesity
and diabetes. Increased leukocyte and platelet recruitment are associat-
ed to markedly enhanced vascular permeability after ischemia reperfu-
sion. Finally, in the presence of risk factors the beneﬁcial effects of
ischemic preconditioning are severely attenuated [105].References
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